Erasca reports positive Phase 1 data for pan-RAS glue ERAS-0015: 62% uORR in 2L+ KRAS G12X NSCLC

Erasca, Inc.

62% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X NSCLC at PADs 16-32 mg QD (N=37), exceeding RMC-6236 by 24 ppt.
40% unconfirmed ORR at 14 weeks in 2L KRAS G12X PDAC at PADs (N=20), exceeding comparator by 11 ppt.
100% of patients (14/14) at PADs showed ≥75% reduction in KRAS G12X ctDNA; 5 showed 100% reduction.
No DLTs; well-tolerated with no discontinuations due to TRAEs; one Grade 5 pneumonitis event after withdrawal of care.
Monotherapy RDEs set at 24 and 32 mg QD; expansion and combo dose escalation initiated ahead of guidance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.